Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses

NCT ID: NCT07221097

Last Updated: 2025-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-29

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from nasopharyngeal swab (NPS) in transport medium.

This study aims to evaluate the diagnostic accuracy of the assays comprising the BioFire ECoV Panel. It is hypothesized that the BioFire ECoV Panel assays will be highly sensitive and specific for the detection of the coronaviruses included on the panel.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this observational, non-interventional study is to evaluate the diagnostic accuracy of the assays comprising the BioFire ECoV Panel when used to test NPS obtained from individuals with signs and/or symptoms of respiratory infection. Multiple geographically distinct clinical sites in the U.S. will participate in testing. Enrollment will consist of residual, coded NPS specimens leftover from standard of care testing for a suspected respiratory infection as determined by a health care provider. Concordance between the BioFire ECoV Panel assays and comparator methods will be measured using positive and negative percent agreement (PPA and NPA).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Respiratory Infection COVID

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suspected respiratory infection

NPS specimens leftover from SOC testing for a suspected respiratory infection as determined by a health care provider

Investigational IVD for coronaviruses

Intervention Type DEVICE

Device testing on prospectively collected specimens leftover from standard of care for IVD validation only; results will not influence patient care/management.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational IVD for coronaviruses

Device testing on prospectively collected specimens leftover from standard of care for IVD validation only; results will not influence patient care/management.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BIOFIRE ECoV Panel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Specimen is residual NPS in transport medium (VTM or UTM) left over from standard of care testing under clinician order for respiratory pathogen analysis.
* Specimen has been held at room temperature for less than or equal to 4 hours or 4°C for less than or equal to 72 hours before enrollment.
* At least 1.7 mL of specimen is remaining after standard of care testing and available for use in the study

Exclusion Criteria

* Specimen is unable to be tested within the defined storage parameters
* Insufficient specimen volume for testing
* Transport medium type is unknown
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital Los Angeles

OTHER

Sponsor Role collaborator

George Washington University

OTHER

Sponsor Role collaborator

Wake Forest University Health Sciences

OTHER

Sponsor Role collaborator

Tampa General Hospital

OTHER

Sponsor Role collaborator

The University of Texas Medical Branch, Galveston

OTHER

Sponsor Role collaborator

Emory University

OTHER

Sponsor Role collaborator

BioFire Defense LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brittany C Collins, PhD

Role: PRINCIPAL_INVESTIGATOR

BioFire Defense LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital Los Angeles

Los Angeles, California, United States

Site Status RECRUITING

George Washington University

Washington D.C., District of Columbia, United States

Site Status RECRUITING

Tampa General Hospital

Tampa, Florida, United States

Site Status NOT_YET_RECRUITING

Emory University Hospital

Atlanta, Georgia, United States

Site Status RECRUITING

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Site Status NOT_YET_RECRUITING

University of Texas Medical Branch

Galveston, Texas, United States

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Brittany C Collins, PhD

Role: CONTACT

801-262-3592

David Rabiger, PhD

Role: CONTACT

801-262-3592

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jenn Dien Bard, PhD D(ABMM) F(CCM)

Role: primary

(323) 361-5443

Aileen Chang, MD MSPH FACP

Role: primary

(202) 677-6562

Suzane Silbert, PhD

Role: primary

(813) 844-4261

Colleen Kraft, MD MSc

Role: primary

(404) 712-8889

John Williamson, PharmD

Role: primary

336-716-2700

Corri Levine, PhD MS MPH

Role: primary

(409) 747-1928

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

75A50122C00073

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

DF-SDY-034538

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Rapid, Onsite COVID-19 Detection
NCT04460690 COMPLETED NA